

Consolidated Financial Result Digest FY2026/3 1Q

(Fiscal Year Ended March 31, 2026)

Aug. 1, 2025




Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based on the company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The company will neither assume nor compensate any loss of anybody resulting from decision based on information provided here.

Our Business Segments

Electronics

Developing, manufacturing, purchasing and selling chemicals that used in printed circuit boards (PCB) and other electronic components



Medical and Pharmaceuticals

Manufacturing and marketing ethical pharmaceuticals, contract development and manufacturing organization (CDMO), manufacturing and selling dental prosthetics



ICT and Sustainability

Businesses included ICT, fine chemicals, energy, and food, etc.



FY2026/3 1Q Overview

Electronics

- Net sales increased by 4% year on year
<Reasons> While the yen appreciated, sales volume of rigid and PKG products increased.
rigid products:
 - + Sales volume increased, mainly for automotive and smartphone products.
 - Sales volume for display (white dry film) products decreased.
PKG products:
 - + Demand increased, mainly for memory products, including brought-forward demand due to tariff policies, resulting in higher sales volume.
Foreign exchange Effects:
 - The appreciation of the yen had a negative impact on business results.
Average exchange rate during the first quarter:
<FY2025/3> 156.5 JPY/USD <FY2026/3> 145.2 JPY/USD
- Won 21st JPCA Award for DF-type-SR for automotive PKG substrates

Medical and Pharmaceuticals

- Net sales increased by 14% year on year
<Reasons> Contract manufacturing business saw an increase in contract volume.
Contract manufacturing business:
 - + Contract volume from exiting customers increased.
 - + The start of full-scale contract manufacturing for new customers resulted in an increase in contract volume.
Manufacturing and marketing business:
 - + Sale volume increased due to higher demand in line with supply shortages of drugs with the same indications at other companies as well as an increase in supply volume of cough suppressants.
 - Sales volume decreased for items subject to the elective care scheme, which was implemented from October 2024.

Company

- Revised forecast for the fiscal year ended March 31, 2026 (FY 2026)
Revised in consideration of higher-than-expected results of the Electronics business and the occurrence of corporate action expenses
- Change of President and CEO, and revision to the composition of the Board Directors
- Establishment of a 2030 Committee and update on its progress

Consolidated Financial Results Summary

	①	②	②-①	(②-①)/①	③	②/③	④	②/④
Unit : JPY Million	2025/3 1Q Result	2026/3 1Q Result	YoY	% of Changes	2026/3 1 st Half Forecast (Announced on April 30)	% of Progress	2026/3 Full Year Forecast (Announced on April 30)	% of Progress
Net Sales	30,854	33,179	2,325	8%	62,500	53%	123,400	27%
Operating Income	6,358	7,055	696	11%	11,800	60%	23,300	30%
Ordinary Income	6,183	6,657	473	8%	11,500	58%	22,500	30%
Net Income	4,605	4,636	31	1%	8,500	55%	16,000	29%
Exchange rate of JPY/USD	156.5	145.2	(11.3)		145.0		145.0	
EBITDA	8,589	9,176	586	7%	16,000	57%	31,900	29%
Operating Income Margin	21%	21%			19%		19%	
EBITDA Margin	28%	28%			26%		26%	

Performance by Segment


Cumulative Net Sales, Operating Income and EBITDA

		①	②	②-①	(②-①)/①	③	②/③	④	②/④
Unit : JPY Million		2025/3 1Q Result	2026/3 1Q Result	YoY	% of Changes	2026/3 1 st -Half Forecast (Announced on April 30)	% of Progress	2026/3 Full-Year Forecast (Announced on April 30)	% of Progress
Electronics	Net Sales	21,451	22,232	781	4%	40,900	54%	81,500	27%
	Operating Income	6,088	6,201	113	2%	10,100	61%	20,100	31%
	Operating Income Margin	28%	28%			25%		25%	
	EBITDA	6,917	7,096	179	3%	11,800	60%	23,800	30%
	EBITDA Margin	32%	32%			29%		29%	
Medical and Pharmaceuticals	Net Sales	8,261	9,419	1,157	14%	18,500	51%	35,400	27%
	Operating Income	579	1,378	799	138%	2,700	51%	4,600	30%
	Operating Income margin	7%	15%			15%		13%	
	EBITDA	1,751	2,356	604	35%	4,600	51%	8,600	27%
	EBITDA Margin	21%	25%			25%		24%	
ICT and Sustainability	Net Sales	1,141	1,527	386	34%	-	-	-	-
	Operating Income	69	(32)	(101)	(147%)	-	-	-	-
	Operating Income Margin	6%	(2%)			-	-	-	-
Company Expense	Operating Income / Loss	(378)	(492)	(114)		-	-	-	-

Trend of Quarterly Performance

Net Sales and Operating Income

Unit : JPY Million



BS- Comparison with the Previous Term

Unit : JPY Million

	2025/3	2025/6	Changes		2025/3	2025/6	Changes
Cash and Deposits	44,903	36,540	(8,363)	Notes and Account Payable	8,505	9,395	890
Accounts Receivables* ¹	27,896	33,357	5,460	Short Term Borrowings* ³	17,634	15,537	(2,096)
Inventory* ²	21,345	20,942	(403)	Long Term Borrowings	46,888	46,624	(264)
Others	3,862	2,961	(900)	Others	16,015	16,088	72
Total Current Assets	98,008	93,801	(4,206)	Total Liabilities	89,043	87,645	(1,398)
Tangible Fixed Assets	67,638	67,251	(386)	Shareholders Equity	94,011	90,240	(3,771)
Intangible Fixed Assets	16,341	15,900	(440)	Accumulated Other Comprehensive Income	8,962	9,722	760
Investments and Other Assets	10,034	10,658	624	Non-Controlling Interest	4	4	(0)
Total Fixed Assets	94,014	93,811	(203)	Total Net Assets	102,978	99,967	(3,011)
Total Assets	192,022	187,612	(4,409)	Total Liabilities and Net Assets	192,022	187,612	(4,409)
				Equity to Asset Ratio	53.6%	53.3%	(0.3%)

*1 Accounts Receivables : Notes Receivable + Accounts Receivable-Trade + Contract Asset

*2 Inventories : Merchandise and Finished Goods + Work in Process + Raw Materials and Supplies

*3 Short-Term Borrowings : Short-Term Borrowings + Long-Term Borrowings Scheduled to Be Repaid within One Year

Revised Forecast for the 1st Half of Fiscal Year Ended March 31, 2026 (FY 2026)

- ✓ We have revised the 1st-half forecast for FY 2026. The reasons for revision are as follows.
- Results for Electronics business are expected to exceed the forecasts announced on April 30, 2025.
 - Corporate action expenses^{*1} are also expected to be incurred in the second quarter.

Unit : JPY Million		2026/3 1 st -half Forecast (Announced on April 30) ^{*2}		2026/3 1 st -half Forecast (Announced on Aug. 1) ^{*3}		Change Ratio	
		Amount	Profit ratio	Amount	Profit ratio	Amount	Ratio
Consolidated	Net Sales	62,500		64,800		+2,300	+4%
	Operating Income	11,800	19%	13,200	20%	+1,400	+12%
	Ordinary Income	11,500	18%	12,700	20%	+1,200	+10%
	Net Income	8,500	14%	8,900	14%	+400	+5%
	EBITDA	16,000	26%	17,400	27%	+1,400	+9%
Electronics	Net Sales	40,900		43,200		+2,300	+6%
	Operating Income	10,100	25%	11,500	27%	+1,400	+14%
	EBITDA	11,800	29%	13,200	31%	+1,400	+12%
Medical and Pharmaceuticals	Net Sales	18,500		18,500		-	-
	Operating Income	2,700	15%	2,700	15%	-	-
	EBITDA	4,600	25%	4,600	25%	-	-

*1 Advisory fees and other related expenses associated with the consideration of proposals and various agenda items at the 79th Ordinary General Shareholders' Meeting, which were recorded as extraordinary losses in the first quarter.

*2 145.0 JPY/USD

*3 Revised by replacing first quarter forecasts of Electronics business with the actual results (145.2 JPY/USD) and remaining the 2nd-quarter forecast (145.0 JPY/USD) unchanged from that disclosed on April 30, 2025.

Revised Forecast for the Fiscal Year Ended March 31, 2026 (FY 2026)

- ✓ We have revised the full-year forecast for FY 2026. The reasons for revision are as follows.
- Results for Electronics business are expected to exceed the forecasts announced on April 30, 2025.
 - Corporate action expenses^{*1} are also expected to be incurred from the second quarter onward.

Unit : JPY Million		2026/3 Full-Year Forecast (Announced on April 30) ^{*2}		2026/3 Full-Year Forecast (Announced on Aug. 1) ^{*3}		Change Ratio	
		Amount	Profit ratio	Amount	Profit ratio	Amount	Ratio
Consolidated	Net Sales	123,400		125,700		+2,300	+2%
	Operating Income	23,300	19%	24,700	20%	+1,400	+6%
	Ordinary Income	22,500	18%	23,700	19%	+1,200	+5%
	Net Income	16,000	13%	16,000	13%	-	-
	EBITDA	31,900	26%	33,300	26%	+1,400	+4%
Electronics	Net Sales	81,500		83,800		+2,300	+3%
	Operating Income	20,100	25%	21,500	26%	+1,400	+7%
	EBITDA	23,800	29%	25,200	30%	+1,400	+6%
Medical and Pharmaceuticals	Net Sales	35,400		35,400		-	-
	Operating Income	4,600	13%	4,600	13%	-	-
	EBITDA	8,600	24%	8,600	24%	-	-

*1 Advisory fees and other related expenses associated with the consideration of proposals and various agenda items at the 79th Ordinary General Shareholders' Meeting, which were recorded as extraordinary losses in the first quarter.

*2 145.0 JPY/USD

*3 Revised by replacing first quarter forecasts of Electronics business with the actual results (145.2 JPY/USD) and remaining the 2nd- to the 4th-quarter forecast (145.0 JPY/USD) unchanged from that disclosed on April 30, 2025.

Change of President and CEO and Revision to the Composition of the Board Directors

- ✓ The Board of Directors has resolved to change our President and CEO at the meeting held on June 21, 2025. Also, independent outside board directors now constitute a majority of the Board of Directors of the company.



Hitoshi Saito
President and CEO



Keiko Tsuchiya
Independent Outside Board Director



Misae Maruyama
Independent Outside Board Director



Noriaki Shimamura
Board Director
(Audit & Supervisory
Committee Member)



Hidenori Sugiura
Independent Outside Board Director
(Audit & Supervisory
Committee Member)




Ikumi Sato
Independent Outside Board Director
(Audit & Supervisory
Committee Member)

Establishment of 2030 Committee

- ✓ We have established the 2030 Committee to examine and address various management challenges, including the formulation of a medium-term management plan, with the aim of realizing our long-term management plan for 2030 in June 2025, aside from the Special Committee. We have built a process that ensures objectivity and transparency and a system that leverages the knowledge of outside experts.

■ Review structure based on the establishment of the 2030 Committee



*Please refer to the "2030 Committee Interim Report" disclosed on August 1st 2025, for details.

Progress of 2030 Committee

- ✓ We have established six working groups (WGs). So far, we have mainly reviewed (1) WG for strengthening the foundation, (2) WG for growth strategy and business portfolio, (4) WG for governance, (5) WG for shareholder and investor relations. Matters regarding mid-term business plans will be reported at the end of August.

1 WG for strengthening the foundations

Targ et Development of self-sufficient personnel and digital transformation, which support the foundation of the company's continued growth

prog ress Gained an understanding of the mechanisms and environment through which we have developed the "self-sufficient personnel" and reviewed activities to date as well as future priority measures

2 WG for growth strategy and business portfolio

Targ et Growth strategy and an ideal business portfolio

prog ress Gained an understanding of the business environment in the Electronics business, the strategies for "manufacturing and marketing" and "contract manufacturing" in the Medical and Pharmaceuticals business, and quantitative aspects of these businesses, and commenced discussions

3 WG for capital allocation

Targ et Optimal capital allocation based on WG for growth strategy and business portfolio and shareholder return policy

prog ress Scheduled to be reviewed following (2)

4 WG for governance

Targ et Measures to establish a corporate governance structure that earns stronger trust from general shareholders

prog ress Reviewed the initiatives to establish a governance system and enhance the effectiveness of the succession plan

5 WG for shareholder and investor relations

Targ et Contents of dialogue with shareholders and investors, and disclosure

prog ress Reviewed the status of dialogue with shareholders and investors to date, and considered measures to further enhance dialogues

6 WG for capital policy

Targ et Capital policy to be adopted from the perspective of enhancing corporate value and securing shareholders' common interests through the achievement of Beyond Imagination 2030.

prog ress Scheduled to be reviewed following (2)

*Please refer to the "2030 Committee Interim Report" disclosed on August 1st 2025, for details.



Electronics

Electronics Terminology


Term	Definition
PCB	<u>P</u> rinted <u>C</u> ircuit <u>B</u> oard
SR	<u>S</u> older <u>R</u> esist, also known as Solder Mask
PKG	Semiconductor <u>P</u> ack <u>a</u> ge
DF	<u>D</u> ry <u>F</u> ilm
BU	<u>B</u> uild- <u>u</u> p

Electronics Product Classification

Group	Category		Type	Remarks
PCB insulating materials	Rigid	Regular	Liquid	<ul style="list-style-type: none"> ▪ SR materials for insulation and surface protection use ▪ Marking, etching and plating materials ▪ Electronic materials etc.
		High end	Liquid／DF	
	PKG		Liquid／DF	
	FPC (Flexible printed circuit board)		Liquid／DF	
	BU		Liquid／DF	<ul style="list-style-type: none"> ▪ Build-up materials for interlayer insulation and hole plugging use
Other related products	Others		Liquid／DF	<ul style="list-style-type: none"> ▪ Conductive paste etc.


Electronics Net Sales by Product Category

Unit : JPY Million



Electronics Net Sales by Sales Area

Unit : JPY Million




Won the 21st JPCA Award

- ✓ Taiyo Ink Mfg. was awarded the 21st JPCA Award by the Japan Electronics Packaging and Circuits Association. This marks the sixth consecutive year in which Taiyo Ink Mfg. has won the award.

Market for Automotive PCBs

- The market has been expanding due to the progress of automotive electrification and digitalization*¹
million m²



- With the development of autonomous driving and ADAS*², the importance of **SR for automotive IC PKG substrates** is increasing

[Required characteristics]

- High durability under harsh conditions such as extreme temperature changes
- High insulation reliability supporting high-speed and high-precision data processing as the integration of electronic components advances

What Taiyo Ink Mfg. has developed

“ Highly reliable dry-film-type solder resist for automotive IC packages ”

[Key features of the products]


- Superior durability and insulation reliability required for SR for automotive PKG substrates
- Compliance with AEC-Q100 Grade 0*³** quality standards

*1 Source: Fuji Chimera Research Institute, Inc. *Shasai denso debaisu & componentsu sochosa 2024* [Comprehensive survey of automotive electronic devices and components 2024]

*2 ADAS: Advanced Driver Assistance Systems

*3 AEC-Q100: Quality standards for automotive electronic components established by the Automotive Electronics Council (AEC). This award-winning product meets the Grade 0 requirements, which are the strictest among these standards.





Medical and Pharmaceuticals


Medical and Pharmaceutical Terminology

Term	Definition
LLP	<u>L</u> ong <u>L</u> isted <u>P</u> roduct A drug for which the patent or re-examination period has expired, enabling the sale of generic drugs
CDMO	<u>C</u> ontract <u>D</u> evelopment <u>M</u> anufacturing <u>O</u> rganization Organizations contracted to manufacture and develop pharmaceutical formulations
GMP	<u>G</u> ood <u>M</u> anufacturing <u>P</u> actice Standards for manufacturing control and quality of pharmaceuticals and quasi-drugs

Medical and Pharmaceuticals Net Sales by Company

Unit : JPY Million

1Q YoY QoQ



mystarz (Dental Business)	+47 [+13%]	+47 [+13%]
Taiyo Pharma Tech (CDMO)	+1,149 [+25%]	+1,906 [+49%]
Taiyo Pharma (Manufacturing and Marketing)	(39) [(1%)]	+482 [+18%]



Company

Received an MSCI ESG Rating of A

- ✓ Taiyo Holdings received an A rating in the MSCI ESG Ratings* issued by MSCI. Our sustainability initiatives, including those related to the environment and corporate governance, have been recognized.

MSCI
ESG RATINGS



CCC	B	BB	BBB	A	AA	AAA
-----	---	----	-----	----------	----	-----

The use of data from MSCI ESG Research LLC or its affiliates ("MSCI"), or the use of MSCI logos, trademarks, service marks, or index names by Taiyo Holdings does not constitute sponsorship, endorsement, recommendation, or promotion of Taiyo Holdings by MSCI. MSCI's services and data are the property of MSCI or its information providers and are provided "as is" without warranty. The name "MSCI" and the MSCI logos are trademarks or service marks of MSCI.

Key initiatives

E Environment	<ul style="list-style-type: none">Strengthening the management and supervision through the establishment of the Sustainability Promotion CommitteeMaintaining and expanding floating solar power plants
S Society	<ul style="list-style-type: none">Continuing investment in human capitalContributing to the local community
G Governance	<ul style="list-style-type: none">Transition to a company with an Audit and Supervisory CommitteeAppointment of the board chairperson from among the outside board directors

*MSCI ESG Ratings are provided by MSCI through investigation and analysis of companies' initiatives related to the environment, society, and governance. Companies are assigned one of seven ratings, from the highest rating of AAA to the lowest rating of CCC. These ratings are regarded as a global benchmark for ESG investment.

Sponsored an eSports Competition “Street Fighter League: Pro-JP 2025”

- ✓ We are continuing our sponsorship of “Street Fighter League: Pro-JP 2025,” an esports competition organized by CAPCOM CO., LTD., as its top partner from the previous season. This season will mark our fifth year of sponsoring it.



Date	Competition
December 13-14, 2025	Street Fighter League: Pro-JP 2025 Playoffs
January 31, 2026	Street Fighter League: Pro-JP 2025 Grand Final

“Street Fighter League: Pro-JP 2024” official website : <https://sf.esports.capcom.com/sfl>

